Accounts Receivable, after Allowance for Credit Loss, Current of ZEVRA THERAPEUTICS, INC. from 31 Dec 2016 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
ZEVRA THERAPEUTICS, INC. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 31 Dec 2016 to 31 Dec 2024.
  • ZEVRA THERAPEUTICS, INC. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 31 Dec 2024 was $10,176,000, a 37% decline year-over-year.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

ZEVRA THERAPEUTICS, INC. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $10,176,000 -$5,943,000 -37% 31 Dec 2024 10-K 12 Mar 2025 2024 FY
Q4 2023 $16,119,000 +$8,934,000 +124% 31 Dec 2023 10-K 12 Mar 2025 2024 FY
Q3 2023 $3,100,000 30 Sep 2023 10-Q 07 Nov 2023 2023 Q3
Q2 2023 $1,300,000 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q4 2022 $7,185,000 +$5,764,000 +406% 31 Dec 2022 10-K 01 Apr 2024 2023 FY
Q4 2021 $1,421,000 -$1,021,000 -42% 31 Dec 2021 10-K 07 Mar 2023 2022 FY
Q4 2020 $2,442,000 +$761,000 +45% 31 Dec 2020 10-K 31 Mar 2022 2021 FY
Q4 2019 $1,681,000 +$1,681,000 31 Dec 2019 10-K 12 Mar 2021 2020 FY
Q4 2018 $0 -$2,005,000 -100% 31 Dec 2018 10-K 28 Feb 2020 2019 FY
Q1 2018 $1,511,000 31 Mar 2018 10-Q 11 May 2018 2018 Q1
Q4 2017 $2,005,000 -$2,998,000 -60% 31 Dec 2017 10-K 01 Mar 2019 2018 FY
Q3 2017 $2,503,000 30 Sep 2017 10-Q 09 Nov 2017 2017 Q3
Q4 2016 $5,003,000 31 Dec 2016 10-K 30 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.